An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Trial Status: closed to accrual
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in
combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or
stage IVB cervical cancer.
The trial consists of two-parts a dose escalation part and an expansion part. The
expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of
the combinations have been determined in the dose escalation part.
Inclusion Criteria
Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after standard of care treatments or are ineligible or intolerant to standard of care for recurrent or stage IVB cervical cancer (Arms A, B and C only).
Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D, E, and H only).
Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after at least one but no more than two prior systemic therapies for recurrent or stage IVB cervical cancer (Arms F and G only).
Must have baseline measurable disease per RECIST v1.1.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All Arms).
Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
Participants of childbearing potential must agree to use adequate contraception during and for 6 months after the last dose of trial treatment administration.
Must sign an informed consent form (ICF) indicating the trial subject understands the purpose of and procedures required for the trial and are willing to participate in the trial (All Arms).
Exclusion Criteria
Has clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage. (All Arms)
Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal surgery are permitted. (All Arms)
Has clinically significant bleeding issues or risks
Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or more) (Arm A and bevacizumab-eligible participants in Arm H)
Recent (within 4 weeks of first dose of trial treatment) clinically significant gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arms A and H only)
Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing complications that require medical intervention (Arms A and H only)
Has active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible (All Arms).
Clinically significant cardiac disease
Requires anti-coagulation therapy (Arms A and H only)
Additional locations may be listed on ClinicalTrials.gov for NCT03786081.
Locations matching your search criteria
United States
Ohio
Cleveland
Case Comprehensive Cancer Center
Status: Active
Name Not Available
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Name Not Available
The dose escalation part will occur in participants with cervical cancer who have
progressed during or after standard of care therapy and who are intolerant or ineligible
to receive standard of care treatments. Arm A will be conducted by escalating doses of
both tisotumab vedotin and bevacizumab. Dose escalations of the tisotumab vedotin +
pembrolizumab and tisotumab vedotin + carboplatin combinations (Arms B and C,
respectively) will be conducted by combining fixed doses of either pembrolizumab or
carboplatin with increasing doses of tisotumab vedotin.
The dose expansion part of this study (Arms D through H) will be conducted in 2
populations: participants with cervical cancer who have not received prior systemic
therapy for recurrent or stage IVB cervical cancer (Arms D, E, and H) and participants
with cervical cancer who have progressed on or after at least 1 but no more than 2 prior
systemic therapies (Arms F and G).
Participants enrolled to Arms D, E, F and H will receive the RP2D of tisotumab vedotin
established in the dose escalation part. Participants enrolled to Arm G will receive
tisotumab vedotin weekly (at a dose lower than subjects in all other Arms) for three
weeks and 1 week off (28-day treatment cycle).
Trial PhasePhase I/II
Trial Typetreatment
Lead OrganizationSeagen, a wholly owned subsidiary of Pfizer
